Christopher Lynch Sells 3,837 Shares of Tenet Healthcare (NYSE:THC) Stock

Tenet Healthcare Corporation (NYSE:THC) Director Christopher Lynch sold 3,837 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.44, for a total value of $934,079.28. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $2,329,233.92. This represents a 28.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Tenet Healthcare Stock Performance

Shares of Tenet Healthcare stock opened at $257.37 on Thursday. The stock has a market capitalization of $22.17 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 1.02 and a beta of 1.27. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. The business has a 50-day moving average of $188.99 and a 200 day moving average of $198.60. Tenet Healthcare Corporation has a 12 month low of $155.02 and a 12 month high of $262.68.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.26 by $1.86. The business had revenue of $6.04 billion for the quarter, compared to analysts’ expectations of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.02 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. As a group, sell-side analysts forecast that Tenet Healthcare Corporation will post 20.62 earnings per share for the current year.

Key Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong earnings underpin the rally: Tenet’s latest quarterly results showed EPS of $6.12, well above the $4.26 consensus estimate, while revenue of $6.04 billion also exceeded expectations. Revenue increased 6.8% year over year, and the company raised its 2026 outlook, reinforcing confidence in operating performance and cost discipline. Tenet Healthcare earnings and outlook
• Positive Sentiment: Analysts raised price targets: Truist lifted its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” Baird increased its target to $280 from $210, although it retained a neutral rating. The revisions reflect improved earnings expectations following Tenet’s results. Analyst price-target updates
• Positive Sentiment: Growth and momentum remain favorable: Zacks highlighted THC as a potentially attractive growth, value and momentum stock based on earnings estimates, estimate revisions and recent price strength. Tenet’s shares recently reached a 52-week high, which may continue to draw momentum-focused investors. Zacks growth analysis
• Neutral Sentiment: Valuation and consensus outlook: THC trades at roughly 10 times earnings, while 17 analysts rate the stock “buy” and three rate it “hold.” The average price target is approximately $268.50, suggesting analysts remain constructive but that much of the near-term upside may already be reflected in the share price. Zacks value analysis
• Negative Sentiment: Insider selling creates an overhang: EVP Paola M. Arbour sold 10,878 shares for about $2.65 million, reducing her holdings by 37.14%. Director Christopher Lynch sold 3,837 shares valued at approximately $934,000, cutting his position by 28.62%. The sales may be personal transactions, but their size could weigh on sentiment after the recent run-up. Tenet Healthcare insider filing

Analyst Upgrades and Downgrades

THC has been the topic of a number of recent research reports. UBS Group upped their price objective on Tenet Healthcare from $288.00 to $308.00 and gave the stock a “buy” rating in a research report on Monday. Stephens reissued an “overweight” rating and set a $285.00 target price on shares of Tenet Healthcare in a research note on Monday. Truist Financial increased their price target on Tenet Healthcare from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group reissued a “buy” rating and set a $305.00 price objective on shares of Tenet Healthcare in a research report on Tuesday. Finally, Weiss Ratings cut shares of Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 2nd. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $268.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in THC. Triumph Capital Management acquired a new stake in shares of Tenet Healthcare during the 3rd quarter worth about $25,000. Activest Wealth Management acquired a new position in Tenet Healthcare in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new stake in Tenet Healthcare during the fourth quarter worth approximately $29,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tenet Healthcare during the 2nd quarter worth approximately $35,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Tenet Healthcare by 146.2% in the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after buying an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 95.44% of the company’s stock.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.